中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝癌研究的变迁与趋势

汤钊猷

引用本文:
Citation:

肝癌研究的变迁与趋势

DOI: 10.3969/j.issn.1001-5256.2014.03.001
详细信息
  • 中图分类号: R735.7

Studies on liver cancer: evolution and perspectives

  • 摘要:

    半个世纪以来肝癌研究发生了很大变迁,概述了主要变迁和今后趋势。(1)肝癌高危险因素已变为HBV与HCV感染、环境因素、生活方式、代谢内分泌和遗传因素,由此须调整预防措施。(2)美国、意大利和作者单位资料表明,肝癌预后的改善主要由于早诊早治,并继续成为提高疗效的重要途径。(3)保守治疗格局在变,分子靶向治疗是一个趋势。"杀癌+杀癌"的联合治疗仍有发展空间,而"杀癌+改造"的模式更值得关注。(4)癌转移观念已有更新,如转移乃全身性问题,转移不是晚期现象,免疫炎症微环境影响转移,转移主要与肿瘤干细胞有关,转移潜能可双向变。为此应重视全身性干预,包括神经、免疫、内分泌、代谢等;关注肿瘤干细胞的"改邪归正";关注抗炎剂的应用;关注中医中药。(5)杀癌疗法负面问题的干预是提高现有疗法疗效的一条捷径。"变"是绝对的,"不变"是相对的,站得高一点,看的远一点,有助推动事物发展。

     

  • [1]CLIFFORD RJ, ZHANG J, MEERZAMAN DM, et al.Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma[J].Hepatology, 2010, 52 (6) :2034-2043.
    [2]HOSAKA T, SUZUKI F, KOBAYASHI M, et al.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J].Hepatology, 2013, 58 (1) :98-107.
    [3]OGAWA E, FURUSYO N, KAJIWARA E, et al.Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C:a prospective, multicenter study[J].J Hepatol, 2013, 58 (3) :495-501.
    [4]ROHR-UDILOVA N, SIEGHART W, EFERL R, et al.Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma[J].Hepatology, 2012, 55 (4) :1112-1121.
    [5]ALTEKRUSE SF, MCGLYNN KA, DICKIE LA, et al.Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008[J].Hepatology, 2012, 55 (2) :476-482.
    [6]SANTI V, BUCCIONE D, DI MICOLI A, et al.The changing scenario of hepatocellular carcinoma over the last two decades in Italy[J].J Hepatol, 2012, 56 (2) :397-405.
    [7]GIANNINI EG, FARINATI F, TREVISANI F.Alpha-fetoprotein in hepatocellular carcinoma surveillance:wake not the dead[J].Hepatology, 2011, 54 (1) :376-377.
    [8]SHANG S, PLYMOTH A, GE S, et al.Identification of osteopontin as a novel marker for early hepatocellular carcinoma[J].Hepatology, 2012, 55 (2) :483-490.
    [9]POMPILI M, SAVIANO A, de MATTHAEIS N, et al.Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma≤3 cm.Results of a multicenter Italian survey[J].J Hepatol, 2013, 59 (1) :89-97.
    [10]KIM YS, LIM HK, RHIM H, et al.Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma:analysis of prognostic factors[J].J Hepatol, 2013, 58 (1) :89-97.
    [11]KOMATSU S, FUKUMOTO T, DEMIZU Y, et al.Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma[J].Cancer, 2011, 117 (21) :4890-4904.
    [12]ASGHAR U, MEYER T.Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?[J]J Hepatol, 2012, 56 (3) :686-695.
    [13]IAVARONE M, CABIBBO G, PISCAGLIA F, et al.Field-practice study of sorafenib therapy for hepatocellular carcinoma:a prospective multicenter study in Italy[J].Hepatology, 2011, 54 (6) :2055-2063.
    [14]LACHENMAYER A, TOFFANIN S, CABELLOS L, et al.Combination therapy for hepatocellular carcinoma:additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib[J].J Hepatol, 2012, 56 (6) :1343-1350.
    [15]ZAANAN A, WILLIET N, HEBBAR M, et al.Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma:a large multicenter AGEO study[J].J Hepatol, 2013, 58 (1) :81-88.
    [16]HSU YC, HO HJ, WU MS, et al.Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma[J].Hepatology, 2013, 58 (1) :150-157.
    [17]UCHINO K, TATEISHI R, SHIINA S, et al.Hepatocellular carcinoma with extrahepatic metastasis:clinical features and prognostic factors[J].Cancer, 2011, 117 (19) :4475-4483.
    [18]YE QH, QIN LX, FORGUES M, et al.Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning[J].Nat Med, 2003, 9 (4) :416-423.
    [19]BUDHU A, FORGUES M, YE QH, et al.Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment[J].Cancer Cell, 2006, 10 (2) :99-111.
    [20]KIM H, CHOI GH, NA DC, et al.Human hepatocellular carcinomas with“Stemness”-related marker expression:keratin 19 expression and a poor prognosis[J].Hepatology, 2011, 54 (5) :1707-1717.
    [21]ZHAO Y, WANG X, WANG T, et al.Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization[J].Hepatology, 2011, 53 (2) :493-503.
    [22]ZHANG CH, XU GL, JIA WD, et al.Prognostic significance of osteopontin in hepatocellular carcinoma:a meta-analysis[J].Int J Cancer, 2012, 130 (11) :2685-2692.
    [23]REN N, WU JC, DONG QZ, et al.Association of specific genotypes in metastatic suppressor HTPAP with tumor metastasis and clinical prognosis in hepatocellular carcinoma[J].Cancer Res, 2011, 71 (9) :3278-3286.
    [24]ZHOU H, HUANG H, SHI J, et al.Prognostic value of interleukin 2and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection[J].Gut, 2010, 59 (12) :1699-1708.
    [25]VILLANUEVA A, HOSHIDA Y, BATTISTON C, et al.Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma[J].Gastroenterology, 2011, 140 (5) :1501-1512.
    [26]MOTOMURA T, SHIRABE K, MANO Y, et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J].J Hepatol, 2013, 58 (1) :58-64.
    [27]ONDICOVA K, MRAVEC B.Role of nervous system in cancer aetiopathogenesis[J].Lancet Oncol, 2010, 11 (6) :596-601.
    [28]SPRINZL MF, GALLE PR.Facing the dawn of immunotherapy for hepatocellular carcinoma[J].J Hepatol, 2013, 59 (1) :9-10.
    [29]LIAO CH, YEH CT, HUANG YH, et al.Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells[J].Hepatology, 2012, 55 (3) :910-920.
    [30]ISRAELSEN WJ, VANDER HEIDEN MG.ATP consumption promotes cancer metabolism[J].Cell, 2010, 143 (5) :669-671.
    [31]NIEMAN KM, KENNY HA, PENICKA CV, et al.Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth[J].Nat Med, 2011, 17 (11) :1498-1503.
    [32]YANG TS, LU SN, CHAO Y, et al.A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients[J].Br J Cancer, 2010, 103 (7) :954-960.
    [33]GARCIA-CAO I, SONG MS, HOBBS RM, et al.Systemic elevation of PTEN induces a tumor-suppressive metabolic state[J].Cell, 2012, 149 (1) :49-62.
    [34]DINARELLO CA.Anti-inflammatory agents:present and future[J].Cell, 2010, 140 (6) :935-950.
    [35]JIA QA, REN ZG, BU Y, et al.Herbal compound“Songyou Yin”renders hepatocellular carcinoma sensitive to oxaliplatin through inhibition of stemness[J].Evid Based Complement Altern Med, 2012, 2012:908601.
    [36]JIA QA, WANG ZM, REN ZG, et al.Herbal compound“Songyou Yin”attenuates hepatoma cell invasiveness and metastasis through downregulation of cytokines secreted by activated hepatic stellate cells[J].BMC Complement Altern Med, 2013, 13:89.
    [37]Willyard C.Lifestyle:Breaking the cancer habit[J].Nature, 2011, 471 (7339) :s16-17.
    [38]HUANG XY, HUANG ZL, WANG L, et al.Herbal compound“Songyou Yin”reinforced the ability of interferon-alfa to inhibit the enhanced metastatic potential induced by palliative resection of hepatocellular carcinoma in nude mice[J].BMC Cancer, 2010, 10:580.
    [39]JIA JB, WANG WQ, SUN HC, et al.A novel tripeptide, tyroserleutide, inhibits irradiation-induced invasiveness and metastasis of hepatocellular carcinoma in nude mice[J].Invest New Drugs, 2011, 29 (5) :861-872.
    [40]XIONG W, REN ZG, QIU SJ, et al.Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin[J].BMC Cancer, 2010, 10:219.
    [41]ZHANG W, SUN HC, WANG WQ, et al.Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice[J].Gastroenterology, 2012, 143 (6) :1641-1649.
    [42]ZHANG QB, SUN HC, ZHANG KZ, et al.Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma[J].PLoS One, 2013, 8 (2) :e55945.
    [43]LU L, SUN HC, ZHANG W, et al.Aspirin minimized the prometastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma[J].PLoS One, 2013, 8 (5) :e65023.
  • 加载中
计量
  • 文章访问数:  2448
  • HTML全文浏览量:  7
  • PDF下载量:  788
  • 被引次数: 0
出版历程
  • 出版日期:  2014-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回